![Transparency Market Researchが調査・発行した産業分析レポートです。世界の生物製剤受託製造市場2021年ｰ2031年：種類別（モノクローナル抗体、組換えタンパク質、ワクチン、分子療法、その他[RNAi、アンチセンスRNA、その他]） / Biologics Contract Manufacturing Market (Type: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Molecular Therapy, and Others [RNAi, Antisense RNA, etc.]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031 / MRC2202A032資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/report-contents-53.gif) | • レポートコード：MRC2202A032 • 出版社/出版日：Transparency Market Research / 2021年11月 • レポート形態：英文、PDF、140ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査レポートは、世界の生物製剤受託製造市場を調査対象とし、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、新型コロナウイルス感染症の影響分析、種類別（モノクローナル抗体、組換えタンパク質、ワクチン、分子療法、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成でまとめています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・新型コロナウイルス感染症の影響分析 ・世界の生物製剤受託製造市場規模：種類別（モノクローナル抗体、組換えタンパク質、ワクチン、分子療法、その他） ・世界の生物製剤受託製造市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Biologics Contract Manufacturing Market – Scope of Report
TMR’s report on the global biologics contract manufacturing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global biologics contract manufacturing market for the period 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global biologics contract manufacturing market from 2021 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the biologics contract manufacturing market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global biologics contract manufacturing market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global biologics contract manufacturing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global biologics contract manufacturing market.
The report delves into the competition landscape of the global biologics contract manufacturing market. Key players operating in the global biologics contract manufacturing market have been identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global biologics contract manufacturing market profiled in this report.
Key Questions Answered in Biologics Contract Manufacturing Market Report
What is the sales/revenue generated by biologics contract manufacturing across all regions during the forecast period?
What are the opportunities in the global biologics contract manufacturing market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which type segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Biologics Contract Manufacturing Market – Research Objectives and Research Approach
The comprehensive report on the global biologics contract manufacturing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global biologics contract manufacturing market in terms of type and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global biologics contract manufacturing market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Biologics Contract Manufacturing Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Biologics Contract Manufacturing Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Biologics Contract Manufacturing: Overview
5.2. Trends in Biopharma Contract Manufacturing
5.3. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)
5.4. COVID-19 Pandemic Impact on Industry
6. Global Biologics Contract Manufacturing Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value & Volume Forecast, by Type, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.2. Recombinant Proteins
6.3.3. Vaccines
6.3.4. Molecular Therapy
6.3.5. Others
6.4. Market Attractiveness Analysis, by Type
7. Global Biologics Contract Manufacturing Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value & Volume Forecast, by Region
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness Analysis, by Country/Region
8. North America Biologics Contract Manufacturing Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value & Volume Forecast, by Type, 2017–2031
8.2.1. Monoclonal Antibodies
8.2.2. Recombinant Proteins
8.2.3. Vaccines
8.2.4. Molecular Therapy
8.2.5. Others
8.3. Market Value & Volume Forecast, by Country, 2017–2031
8.3.1. U.S.
8.3.2. Canada
8.4. Market Attractiveness Analysis
8.4.1. By Type
8.4.2. By Country
9. Europe Biologics Contract Manufacturing Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value & Volume Forecast, by Type, 2017–2031
9.2.1. Monoclonal Antibodies
9.2.2. Recombinant Proteins
9.2.3. Vaccines
9.2.4. Molecular Therapy
9.2.5. Others
9.3. Market Value & Volume Forecast, by Country/Sub-region, 2017–2031
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Europe
9.4. Market Attractiveness Analysis
9.4.1. By Type
9.4.2. By Country/Sub-region
10. Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value & Volume Forecast, by Type, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.2. Recombinant Proteins
10.2.3. Vaccines
10.2.4. Molecular Therapy
10.2.5. Others
10.3. Market Value & Volume Forecast, by Country/Sub-region, 2017–2031
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Australia & New Zealand
10.3.5. Rest of Asia Pacific
10.4. Market Attractiveness Analysis
10.4.1. By Type
10.4.2. By Country/Sub-region
11. Latin America Biologics Contract Manufacturing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value & Volume Forecast, by Type, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.2. Recombinant Proteins
11.2.3. Vaccines
11.2.4. Molecular Therapy
11.2.5. Others
11.3. Market Value & Volume Forecast, by Country//Sub-region, 2017–2031
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Market Attractiveness Analysis
11.4.1. By Type
11.4.2. By Country/Sub-region
12. Middle East & Africa Biologics Contract Manufacturing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value & Volume Forecast, by Type, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.2. Recombinant Proteins
12.2.3. Vaccines
12.2.4. Molecular Therapy
12.2.5. Others
12.3. Market Value & Volume Forecast, by Country/Sub-region, 2017–2031
12.3.1. GCC Countries
12.3.2. South Africa
12.3.3. Rest of Middle East & Africa
12.4. Market Attractiveness Analysis
12.4.1. By Type
12.4.2. By Country/Sub-region
13. Competition Landscape
13.1. Company Profiles
13.1.1. Lonza Group
13.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.1.2. Product Portfolio
13.1.1.3. SWOT Analysis
13.1.1.4. Strategic Overview
13.1.2. Samsung Biologics Co., Ltd.
13.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.2.2. Product Portfolio
13.1.2.3. SWOT Analysis
13.1.2.4. Strategic Overview
13.1.3. Patheon by Thermo Fisher Scientific, Inc.
13.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.3.2. Product Portfolio
13.1.3.2. SWOT Analysis
13.1.3.3. Strategic Overview
13.1.4. Cambrex Corporation
13.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.4.2. Product Portfolio
13.1.4.3. SWOT Analysis
13.1.4.4. Strategic Overview
13.1.5. Siegfried Holding AG
13.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.5.2. Product Portfolio
13.1.5.3. SWOT Analysis
13.1.5.4. Strategic Overview
13.1.6. Fujifilm Holding Corporation
13.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.6.2. Product Portfolio
13.1.6.3. SWOT Analysis
13.1.6.4. Strategic Overview
13.1.7. AbbVie, Inc.
13.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.7.2. Product Portfolio
13.1.7.3. SWOT Analysis
13.1.7.4. Strategic Overview
13.1.8. Boehringer Ingelheim
13.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.8.2. Product Portfolio
13.1.8.3. SWOT Analysis
13.1.8.4. Strategic Overview
13.1.9. Recipharm Pharmaceuticals
13.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.9.2. Product Portfolio
13.1.9.3. SWOT Analysis
13.1.9.4. Strategic Overview
13.1.10. WuXi Biologics
13.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.10.2. Product Portfolio
13.1.10.3. SWOT Analysis
13.1.10.4. Strategic Overview
13.1.11. Catalent, Inc.
13.1.11.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.11.2. Product Portfolio
13.1.11.3. SWOT Analysis
13.1.11.4. Strategic Overview